A meningioma diagnosis can turn your world upside down. Headaches that won’t quit, vision changes, seizures, or the shock of learning a tumor is growing in the lining of your brain or spinal cord. For many women, that diagnosis came after years of relying on the Depo-Provera birth control shot for reliable contraception.
If you used Depo-Provera, Depo-SubQ Provera 104, or an authorized generic form of medroxyprogesterone acetate for a year or longer and later developed a meningioma, you are not alone. Thousands of women are pursuing claims in the federal Depo Provera lawsuit. This guide explains the scientific link, who may qualify, the current status of the multidistrict litigation and settlement, and practical next steps. Our goal is to give you clear information so you can decide whether a free case review makes sense for your situation.
Understanding the Link Between Depo-Provera and Meningioma
Depo-Provera is an injectable contraceptive that delivers a high dose of synthetic progesterone (medroxyprogesterone acetate) every three months. It has been widely used for decades because it is effective and convenient. Recent large studies, however, have connected prolonged use to a higher risk of intracranial meningioma.
A major 2024 case-control study published in the British Medical Journal examined French health data and found that women who used injectable medroxyprogesterone acetate for one year or longer had significantly elevated odds of developing meningioma requiring surgery. The odds ratio for the injectable form was 5.55 compared with non-users. The excess risk was driven by prolonged exposure.
A larger 2025 U.S. cohort study published in JAMA Neurology looked at more than 10 million patients. It reported a relative risk of 2.43 for meningioma among depot medroxyprogesterone acetate users compared with controls. The increased risk was most pronounced in women who used the drug for more than four years or who started after age 31. No similar elevation appeared with most other contraceptives.
These findings matter because meningiomas, while often benign (non-cancerous), can still cause serious problems. As the tumor grows, it can press on brain tissue or nerves, producing neurological symptoms such as persistent headaches, vision loss, seizures, weakness, numbness, or cognitive changes. Treatment may involve surgery, radiation, or long-term monitoring. Recovery can be lengthy, and some women face lasting deficits or recurrence.
In December 2025 the FDA added a meningioma warning to the Depo-Provera and Depo-SubQ Provera 104 labels. The label now notes that cases of meningioma have been reported after repeated administration, primarily with long-term use, and advises monitoring and discontinuation if a meningioma is diagnosed.
Plaintiffs in the litigation argue that Pfizer and related companies knew or should have known about the association for years yet failed to provide adequate warnings to patients and doctors in the United States. That alleged Pfizer failure to warn forms the core of the product-liability claims.
Current Status of the Federal Litigation and Settlement
The federal cases are centralized in multidistrict litigation (MDL) No. 3140 in the U.S. District Court for the Northern District of Florida before Judge M. Casey Rodgers. As of late 2026 more than 6,400 lawsuits were pending. The MDL allows coordinated discovery and pretrial rulings while keeping each plaintiff’s individual claim intact. It is not a class action.
In June 2026 Pfizer and plaintiffs’ leadership reached a global settlement in principle covering a majority of the federal claims and certain New York state-court cases. The parties signed a Master Settlement Agreement in July 2026. The terms remain confidential. The parties estimate that roughly 80 percent of the federal plaintiffs will be eligible. Registration for the settlement program must be completed by November 30, 2026. Payments are expected to begin rolling out in the first quarter of 2027.
Not every claim is included. Some cases are excluded based on filing dates or the timing between the last injection and the meningioma diagnosis. Women who are ineligible or who choose to opt out continue in the MDL under separate procedures that require stronger case-specific causation evidence. New lawsuits continue to be filed, so the litigation has not ended for everyone.
Because this is not a class action, eligible women generally work through their own attorneys to register and submit documentation. The settlement administrator (BrownGreer) and related funds handle claims review and distribution.
Who Qualifies for the Depo Provera Lawsuit
Eligibility is determined case by case, but common criteria used by attorneys reviewing claims include:
- Documented use of Depo-Provera, Depo-SubQ Provera 104, or an authorized generic medroxyprogesterone acetate injection.
- Use for roughly one year or longer (often measured as four or more injections, since shots are given every three months). Some firms consider fewer injections depending on the facts.
- A confirmed diagnosis of meningioma of the brain or spinal cord, typically supported by MRI, CT, or pathology reports.
- Filing within the applicable statute of limitations in your state. Deadlines often run from the date of diagnosis or from the date you reasonably discovered (or should have discovered) the possible link to the drug. These periods commonly range from one to three years or longer under discovery rules, but they vary widely.
Women whose tumors required surgery, radiation, or produced lasting neurological injury generally present stronger claims. Family members or estates may pursue claims on behalf of women who have passed away if the death was related to the tumor or its treatment.
If your diagnosis came many years after the last injection, or if your lawsuit was filed after certain cutoff dates, your claim may fall outside the current settlement program. An experienced attorney can still evaluate whether an individual lawsuit remains viable.
Evidence Needed for a Depo-Provera Claim
Strong documentation improves the chance of a favorable outcome, whether inside the settlement or in continued litigation. Useful records include:
- Pharmacy, clinic, or medical records showing the dates and number of injections.
- Imaging reports and pathology confirming the meningioma.
- Treatment records (surgery reports, radiation notes, neurology follow-up).
- Records of neurological symptoms and how they affect daily life or work.
- Any communications with doctors about the possible connection to the birth control shot.
You do not need to gather everything yourself before speaking with a lawyer. Most firms that handle these cases obtain records on your behalf after a free consultation.
Factors That Influence Settlement Value
No official payout grid has been released. Attorney estimates for qualifying claims often range from roughly $150,000 to more than $1 million, depending on the individual facts. Higher values tend to attach to cases involving higher-grade tumors, major surgery, permanent neurological deficits, recurrence, significant lost income, or extensive future care needs. Lower-severity cases (small, asymptomatic tumors managed with observation) typically fall at the lower end of projected ranges.
Other factors include the strength of the exposure records, the clarity of the causation link, and any alternative explanations for the tumor. Because the Master Settlement Agreement is confidential, the exact formula used by the claims administrator is not public. A supplemental compensation fund exists for certain additional payments, but criteria remain private.
These figures are projections based on similar pharmaceutical and meningioma litigation experience. They are not guarantees. Actual awards will depend on the final program rules and the documentation submitted.
How Long Do You Have to File?
The statute of limitations is one of the most time-sensitive issues. Once the deadline passes, courts generally bar the claim. Because the discovery rule often applies (the clock starts when you knew or reasonably should have known of both the injury and its possible cause), the window can differ from a simple date-of-diagnosis calculation.
Women who only recently learned of the BMJ study, the JAMA findings, or the FDA label change may still have time in many states. Waiting is risky. Contacting a lawyer promptly allows a proper review of the deadlines that apply to your specific situation.
Step-by-Step: What to Expect If You Pursue a Claim
- Free case evaluation. You share basic facts about your use of the shot and your diagnosis. Most firms offer this at no cost and with no obligation.
- Records collection. If the firm accepts the case, they request medical and pharmacy records.
- Filing or registration. If your claim fits the settlement criteria and you already have counsel who meets any cutoff, your attorney registers you by the November 30, 2026 deadline. Otherwise a new lawsuit may be filed and may later join the MDL.
- Claims process or continued litigation. Settlement participants submit required forms and documentation. Those outside the settlement proceed under the court’s ongoing case-management orders, which may include expert reports on causation.
- Resolution. Settlement payments are expected to begin in early 2027 for eligible claimants. Individual trials or further settlements remain possible for non-settling cases.
Throughout the process you should not have to appear in court for routine pretrial matters. Your attorney handles the legal work.
Common Pitfalls to Avoid
Do not assume your claim is too late or too small without a professional review. Do not discard old medical records. Be cautious about signing anything from the manufacturer or insurers without legal advice. Avoid online forms that request sensitive medical details without confirming the firm’s credentials and contingency-fee arrangement.
Most product-liability attorneys handling these cases work on contingency. That means you pay no upfront fees; the firm receives a percentage only if they recover compensation for you.
Frequently Asked Questions
Is the Depo Provera lawsuit a class action?
No. It is a multidistrict litigation that consolidates individual lawsuits for pretrial efficiency. Each woman keeps her own claim.
Who qualifies for the Depo Provera lawsuit?
Women who used Depo-Provera, Depo-SubQ Provera 104, or an authorized generic for roughly a year or longer and were later diagnosed with a meningioma brain or spinal cord tumor may qualify, subject to statute-of-limitations and other criteria.
What are possible Depo Provera lawsuit settlement amounts?
Official figures are confidential. Attorney projections for qualifying claims often range from about $150,000 to more than $1 million based on severity, treatment, and documentation.
How long do you have to file a Depo Provera lawsuit?
Deadlines vary by state and often run from the date of diagnosis or discovery of the possible link. Contact a lawyer promptly to check the rules that apply to you.
What evidence is needed for a Depo-Provera claim?
Injection records, diagnostic imaging or pathology confirming meningioma, treatment records, and documentation of symptoms and impact help support the claim.
Can family members file?
In some circumstances spouses, children, or estates may pursue claims related to a deceased woman’s injury or death.
Does the settlement cover everyone?
No. Roughly 20 percent of current federal plaintiffs are estimated to fall outside the program based on filing timing or diagnosis latency relative to last use. New cases continue to be evaluated separately.
You May Also Like: Cash App Unsolicited Text Message Settlement: Eligibility & Payout Guide

